Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS8728021 B2
Type de publicationOctroi
Numéro de demandeUS 12/972,325
Date de publication20 mai 2014
Date de dépôt17 déc. 2010
Date de priorité14 nov. 2003
Autre référence de publicationEP1732634A1, EP1732634A4, US7291125, US7815592, US7850638, US8128588, US8486000, US8758289, US8771218, US8808220, US9351873, US20050107734, US20070088242, US20070106235, US20070106236, US20080195027, US20110028884, US20110087149, US20110087150, US20110087151, US20140188030, US20160346125, WO2005046782A1
Numéro de publication12972325, 972325, US 8728021 B2, US 8728021B2, US-B2-8728021, US8728021 B2, US8728021B2
InventeursMinas Theodore Coroneo
Cessionnaire d'origineTranscend Medical, Inc.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Ocular pressure regulation
US 8728021 B2
Résumé
Disclosed are devices and methods of treating an ocular disorder including forming a self-sealing incision in a cornea into an anterior chamber of an eye; introducing through the incision a fluid drainage tube having a distal end, a proximal end and a longitudinal, internal lumen extending through the fluid drainage tube, wherein at least the proximal end passes through the anterior chamber; and implanting the distal end of the fluid drainage tube in fluid communication with the suprachoroidal space such that the proximal end of the fluid drainage tube remains in fluid communication with the anterior chamber.
Images(5)
Previous page
Next page
Revendications(19)
What is claimed is:
1. A method of treating disease in an eye, comprising:
introducing an ophthalmic implant positioned on a delivery instrument into the anterior chamber of the eye, the ophthalmic implant having an internal lumen through which aqueous humor can flow, a proximal end and a distal end;
penetrating eye tissue at a location proximate the scleral spur of the eye;
bluntly dissecting between a portion of the ciliary body and a portion of the sclera toward the suprachoroidal space; and
positioning the ophthalmic implant from within the anterior chamber until the distal end of the implant is positioned within the suprachoroidal space such that the internal lumen of the ophthalmic implant provides fluid communication between the anterior chamber and the suprachoroidal space.
2. The method of claim 1, wherein bluntly dissecting between a portion of the ciliary body and a portion of the sclera comprises using the delivery instrument to bluntly dissect between the portions.
3. The method of claim 2, wherein penetrating eye tissue at a location proximate the scleral spur of the eye comprises using a distal tip of the delivery instrument to penetrate the eye tissue.
4. The method of claim 3, wherein the delivery instrument is configured to avoid penetrating the portion of the sclera.
5. The method of claim 1, wherein bluntly dissecting between a portion of the ciliary body and a portion of the sclera comprises delivering fluid through a lumen in the delivery instrument to hydraulically create a dissection plane into a portion of the suprachoroidal space.
6. The method of claim 5, wherein the fluid delivered accumulates within the suprachoroidal space.
7. The method of claim 5, wherein the fluid is a viscoelastic substance.
8. The method of claim 1, wherein penetrating eye tissue at a location proximate the scleral spur of the eye comprises injecting a viscoelastic material through the ciliary muscle attachment of the eye using a distal tip of the delivery instrument.
9. A method of treating disease in an eye, comprising:
introducing an ophthalmic implant positioned on a delivery instrument into the anterior chamber of the eye, the ophthalmic implant having an internal lumen through which aqueous humor can flow, a proximal end and a distal end;
delivering a substance through the delivery instrument into a portion of the suprachoroidal space;
forming a passageway between the anterior chamber of the eye and the suprachoroidal space of the eye by hydraulically creating a dissection plane between a portion of the ciliary body and a portion of the sclera into the suprachoroidal space with the substance; and
positioning the ophthalmic implant in the passageway so that the proximal end of the ophthalmic implant is positioned within the anterior chamber and the distal end of the ophthalmic implant is positioned in communication with the suprachoroidal space.
10. The method of claim 9, wherein positioning the ophthalmic implant further comprises orienting the ophthalmic implant such that the internal lumen of the ophthalmic implant provides fluid communication between the anterior chamber and the suprachoroidal space.
11. A method of claim 9, wherein positioning the ophthalmic implant in the passageway is performed after the passageway is formed.
12. A method of claim 9, wherein forming a passageway between the anterior chamber of the eye and the suprachoroidal space comprises performing a cyclodialysis.
13. A method of claim 9, wherein introducing the ophthalmic implant into the anterior chamber of the eye comprises passing a distal end and a proximal end of the ophthalmic implant through the cornea of the eye.
14. A method as in claim 13, wherein passing the distal end and the proximal end of the ophthalmic implant through the cornea comprises sequentially passing the distal end and then the proximal end into the anterior chamber as the implant is being introduced.
15. A method as in claim 14, wherein the distal end and the proximal end of the ophthalmic implant are sequentially passed such that the distal end and proximal end are concurrently located within the anterior chamber.
16. The method of claim 9, wherein forming a passageway between the anterior chamber and the suprachoroidal space comprises detaching the portion of the ciliary body from the portion of the sclera and creating a detached space.
17. The method of claim 16, further comprising positioning the ophthalmic implant from within the anterior chamber until the distal end of the implant is positioned within the detached space between the portion of the ciliary body and the portion of the sclera.
18. The method of claim 16, wherein forming a passageway between the anterior chamber and the suprachoroidal space comprises detaching a portion of choroid from the sclera.
19. The method of claim 9, wherein the substance comprises a viscoelastic substance.
Description
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/615,642, filed Dec. 22, 2006, now U.S. Pat. No. 8,128,588 entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo, which is a continuation of U.S. application Ser. No. 10/712,277, filed Nov. 14, 2003, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo, now U.S. Pat. No. 7,291,125, issued Nov. 6, 2007.

This application also is related to U.S. application Ser. No. 12/972,176, filed on this day herewith, and U.S. application Ser. No. 12/972,261, filed on this day herewith, and U.S. application Ser. No. 12/905,003, filed Oct. 14, 2010, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo; and to U.S. application Ser. No. 10/579,330, filed Nov. 12, 2004, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo; and to U.S. application Ser. No. 11/615,615, Dec. 22, 2006, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo; and to U.S. application Ser. No. 12/107,676, filed on Apr. 22, 2008, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo, now U.S. Pat. No. 7,815,592, issued Oct. 19, 2010.

Where permitted, the subject matter of each of the above noted applications is incorporated by reference in its entirety by reference thereto.

FIELD OF THE INVENTION

This invention is directed to therapeutic methods and devices for the treatment of glaucoma. In particular, this invention is concerned with the use of a shunt or drain for the treatment of glaucoma. In another aspect this invention is concerned with ocular pressure spike shunts and use of the same in ocular surgery.

BACKGROUND OF THE INVENTION

The glaucomas are a common group of blinding conditions usually associated with elevated intraocular pressure. This elevated pressure in the eye may be regarded as a disorder of the drainage system of the eye which gives rise to the glaucomas.

Aqueous humor of the eye (“aqueous”) is a flowing liquid fluid (composed of sodium, chloride, bicarb, amino acids, glucose, ascorbic acid, and water) that is actively secreted by the ciliary body and flows out past the iris into the anterior chamber (are between the lens/iris and the cornea). The aqueous drains out through angle formed by the iris and the sclera into a meshwork call the trabeculum, and from there into the canal of Schlemm and then into the episcleral veins. Uveosclera drainage also occurs. Normal intraocular pressure (TOP) of aqueous in anterior chamber is between 10 and 20 mm Hg. Prolonged IOPs of greater than 21 mm Hg are associated with damage to optic nerve fibers.

In some cases of glaucoma the cause can be found: the trabecular meshwork becomes blocked by pigment or membrane. In other cases, blockage is due to a closure of the angle between the iris and the cornea. This angle type of glaucoma is referred to as “angle-closure glaucoma”. In the majority of glaucoma cases, however, called “open angle glaucoma”, the cause is unknown.

Elevated intraocular pressure results in the death of retinal ganglion cells (which convey retinal information to the brain) resulting in a characteristic pattern of loss of the field of vision, progressing to tunnel vision and blindness if left untreated.

Treatment of glaucoma consists predominantly of methods to lower the intraocular pressure (pharmacological, trabecular meshwork laser and surgery to drain fluid from the eye). More recently protection of the retinal ganglion cells by neuroprotective agents has been attempted.

Although pharmacological treatments of glaucoma have improved, they have important implications for the patient's quality of life, have compliance issues which are important in the elderly (in whom glaucoma is prevalent), expose the patient of glaucoma to side effects, and over a lifetime are costly.

Surgery for glaucoma treatment is usually a trabeculectomy in which a fistula is created to drain fluid from the anterior chamber to the subconjunctival space near the limbus, creating a bulge in the conjunctiva known as a bleb. Frequently scarring occurs and attempts to counter this with antimetabolites such as Mitomycin C have met with some success. In recalcitrant cases, glaucoma implants, drainage, shunt or valve devices have been developed e.g. Molteno (U.S. Pat. No. 4,457,757), Krupin (U.S. Pat. No. 5,454,746) and Baerveldt (U.S. Pat. No. 5,178,604). These suffer from similar problems of scarring (Classen L, Kivela T, Tarkkanen “A Histopathologic and immunohistochemical analysis of the filtration bleb after unsuccessful glaucoma seton implantation” Am J Ophthalmol, 1996; 122:205-12) around the external opening of the tube devices in the subconjunctival space—the development of a large number of these devices is testament to the fact that many fail in the longer term. In these devices a drainage tube is located in the anterior chamber and is in fluid communication with the sclera or a surgically created subconjunctival space.

Whereas cataract surgery has been revolutionized in the last two decades, improvements in glaucoma surgery have been slower. Antifibrotic agents have improved the success rate of conventional filtration surgery (trabeculectomy), but with increased bleb leaks, blebitis, endophthalmitis and hypotensive maculopathy. Glaucoma shunts have had limited success in eyes that have “failed” multiple standard procedures. However complications with malpositioned tubes, erosion and strabismus persist. A considerable issue is the lack of reproducibility and predictability in achieving the desired target intraocular pressure (IOP). Final IOP is largely determined by healing which can be unpredictable—in view of vast biological variations, it is impossible to predict which eyes will rapidly scar causing failure and which will fail to heal resulting in prolonged post-operative hypotony. Scarring remains a significant problem in all these external drainage proposals, where aqueous drains into the conjunctiva, or surgical chambers in the sclera.

The introduction of a new class of antiglaucoma drugs, the prostaglandin analogues, has resulted in acknowledgment of the importance of the uveoscleral pathway in drainage of fluid form the eye (Hylton C, Robin A L “Update on prostaglandin analogs” Curr Opin Ophthalmol, 2003; 14:65-9). Uveoscleral flow where aqueous humor flows through the interstitium of the ciliary muscle into the suprachoroidal space (a potential space between the choroids and sclera) and out through the sclera into the connective tissue of the orbit may account for 54% of outflow young healthy humans (Toris C B, Yablonski M E, Wang Y L, Camras C B “Aqueous humor dynamics in the aging human eye” Am J Ophthalmol, 1999; 127:407-12).

Cyclodialysis, the separation of the ciliary body from the scleral spur and underlying sclera, creates free communication between the anterior chamber and the suprachoroidal space and enhances uveoscleral flow. It has long been known that cyclodialysis can cause a profound reduction of intraocular pressure—initially (Fuchs E. “Detachment of the choroid inadvertently during cataract surgery” [German] von Graefes Arch Ophthalmol, 1900; 51:199-224) cyclodialysis was recognized as a complication of cataract surgery. Deliberate creation of a cyclodialysis cleft for treating elevated intraocular pressure in uncontrolled glaucoma was first described as a surgical procedure in 1905 (Heine I. “Cyclodialysis, a new glaucoma operation” [German]) Dtsch Med Wochenschr, 1905; 31:824-826). Since such clefts can heal and close spontaneously a number of devices have been used to keep them open, including platinum wire, horse hair, magnesium strips, tantalum foil, Supramid®, gelatin film, Teflon®, silicone and polymethylmethacrylate (Rosenberg L F, Krupin T. “Implants in glaucoma surgery” Chapter 88, The Glaucomas, Ritch R, Shields B M, Krupin T Eds. 2nd Edition Mosby St Louis 1986) and Hema (Mehta K R. “The suprachoroidal Hema wedge in glaucoma surgery” American Academy of Ophthalmology meeting 1977, pp 144). However the success rate of such approaches has been low (as low as 15%, Rosenburg & Krupin ibid and Gross R L, Feldman R M, Spaeth G L, et al “Surgical therapy of chronic glaucoma in aphakia and pseudophakia” Ophthalmology, 1988; 95:1195-201). Failure was due to uncontrolled low pressure (hypotony) with consequential macular edema, bleeding (hyphema) and inadequate pressure control.

The device and method of a first aspect of this invention takes advantage of the methods used in cataract surgery to develop a minimally invasive glaucoma procedure—thus small, self sealing incisions and materials that are biocompatible and foldable so that they fit through small openings will reduce surgical trauma and time. The controlled draining of aqueous into the suprachoroidal space according to this invention provides some predictability of outcome and overcomes scarring problems that have plagued glaucoma implants in the past.

The most frequent complication following modern cataract surgery with phacoemulsification, requiring specific treatment is elevated intraocular pressure (Cohen V M, Demetria H, Jordan K, Lamb R J, Vivian A J.: First day post-operative review following uncomplicated phacoemulsification” Eye, 1998; 12 (Pt 4):634-6, and Dinakaran S, Desai S P, Raj P S. “Is the first post-operative day review necessary following uncomplicated phacoemulsification surgery?” Eye, 2000 June; 14 (Pt 3A):364-6). The increase may be marked and typically peaks at 5 to 7 hours before returning to near normal levels in 1 to 3 days (Hildebrand G D, Wickremasinghe S S, Tranos P G, Harris M L, Little B C. “Efficacy of anterior chamber decompression in controlling early intraocular pressure spikes after uneventful phacoemulsification” J Cataract Refract Surg., 2003; 29:1087-92). Such pressure spikes can cause pain and may increase the risk of sight-threatening complications such as retinal vascular occlusion, increases loss of visual field in advanced glaucoma and ischemic optic neuropathy—effects in otherwise healthy eyes are unknown (Hildebrand G D et al, ibid).

A number of prophylactic treatments are used with limited success—these include intracameral carbachol or acetylcholine, topical timolol, dorzolamide, aproclonidine, latanoprost and systemic acetazolamide (see Hildebrand G D et al, ibid). This also exposes the patient to the risk of drug side effects, increased cost and it has been postulated that reducing the flow of aqueous humor post surgery prolongs the residence time of bacteria that frequently (46.3% of cases) contaminate the anterior chamber during surgery (Srinivasan R, Tiroumal S, Kanungo R, Natarajan M K. “Microbial contamination of the anterior chamber during phacoemulsification” J Cataract Refract Surg, 2002; 28:2173-6.). This may increase the risk of endophthalmitis one of the most devastating sequelae of intraocular surgery, since the bacteria are not being “flushed out” of the eye by the normal production of aqueous humour, the secretion of which has been suppressed by the drugs. Another technique is to decompress the anterior chamber by applying pressure to the posterior lip of the paracentesis wound at the appropriate time. This requires surveillance and could increase the risk of infection. Another aspect of this invention hereinafter described overcomes these problems.

SUMMARY OF THE INVENTION

According to the present invention there is provided a flexible ocular device for implantation into the eye formed of a biocompatible elastomeric material, foldable to a diameter of 1.5 mm or less, comprising a fluid drainage tube having at one end a foldable plate adapted to locate the device on the inner surface of the sclera in a suprachoroidal space formed by cyclodialysis, said drainage tube opening onto the disc at one end and opening to the anterior chamber when implanted into the eye at its other end, so as to provide aqueous pressure regulation.

Preferably the fluid drainage tube has a diameter selected to provide predetermined resistance to aqueous humor flow, for example a pressure of 10 mm Hg or less. Alternatively said tube contains a valve so as to regulate pressure of the aqueous chamber at a predetermined level, for example, at no less than 10 mm Hg.

In accordance with another embodiment of this invention there is provided a method for treating glaucoma which comprises:

providing a flexible ocular device formed of a biocompatible elastomeric material foldable to a diameter of 1.5 mm or less, comprising a fluid drainage tube having at one end a foldable plate adapted to locate the device on the inner surface of the sclera and at its other end being open so as to allow fluid communication through said tube;

forming a small self-sealing incision at the juncture of the cornea and sclera of the eye opening into the anterior chamber;

filling the anterior chamber with a viscoelastic substance;

introducing the foldable ocular device into a suprachoroidal space formed by cyclodialysis via a hollow cannula, wherein said plate locates the device on the inner surface of the sclera in the suprachoroidal space, and said drainage tube is located in the anterior chamber of the eye so as to provide aqueous humor pressure regulation; and

thereafter removing said cannula and viscoelastic material from the eye.

In another aspect there is provided an ocular pressure spike shunt for insertion into an ocular paracentesis incision port following ocular surgery, comprising a flexible fluid transfer tube formed of biocompatible material, preferably biocompatible elastomeric material, so as to allow paracentesis incision closure around said tube, having an inner end and an outer end, a tubular lumen disposed between said inner end and said outer end to allow fluid communication through said tube, said lumen containing a valve for controlling pressure in the eye following ocular surgery, which valve opens permitting fluid flow through said tube when a predetermined pressure is exceeded, said shunt being configured such that on insertion into a paracentesis port said outer end is substantially flush with the surface of the cornea, and said inner end opens into the anterior chamber of the eye.

In another aspect there is provided a method for preventing ocular pressure spikes following ocular surgery wherein a paracentesis incision port is formed in the eye during said surgery, comprising introducing an ocular pressure spike shunt into said paracentesis port at the conclusion of ocular surgery, said shunt comprising a flexible fluid transfer tube formed of biocompatible material, preferably biocompatible elastomeric material, so as to allow paracentesis incision closure around said tube, having an inner end and an outer end, a tubular lumen disposed between said inner end and said outer end to allow fluid communication through said tube, said lumen containing a valve for controlling pressure in the eye following ocular surgery, which valve opens permitting fluid flow through said tube when a predetermined pressure is exceeded, said shunt being configured such that on insertion into a paracentesis port said outer end is substantially flush with the surface of the cornea, and said inner end protrudes into the anterior chamber of the eye.

DESCRIPTION OF THE FIGURES

FIG. 1 shows a diagrammatic representation of a side sectional view of suprachoroidal shunt insertion using an injector.

FIG. 2 shows a diagrammatic representation of a side sectional view of an eye showing the unfolded plate portion of the device and a cannula introducing said device across the anterior chamber at 180° to the site of insertion.

FIG. 3 shows a diagrammatic representation of an eye containing a pressure spike shunt inserted into a paracentesis port.

FIG. 4 shows a perspective view of another embodiment of an ocular device described herein.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

The ocular device according to the present invention is implanted in a patient's eye using minimally invasive surgery techniques, adopted from modern cataract surgery.

The ocular device is formed from a biocompatible elastomeric material. Preferably, the device is made of soft surgical grade polymeric material, such as silicon or acrylic material such that the device is foldable and may be rolled up for insertion via a cannula. FIG. 1 shows a proximal end of a cannula forming a cyclodialysis. The folded device may be introduced via such a cannula. The elastomeric material is selected to be sufficiently soft that it does not erode delicate underlying choroid material when inserted into the eye. Such material and ocular lenses formed therefrom are well known and used in cataract surgery.

Sutures are not required to hold the device in place once surgically introduced into the eye, as the foldable plate is adapted to locate the device on the inner surface of the sclera in a suprachoroidal space formed by cyclodialysis (FIG. 2). Preferably, the plate is of a disc-like shape which matches the curvature of the eye once unfolded. FIG. 2 depicts an unfolded disc (connected tube not shown) after cannula introduction across the anterior chamber (transcameral). Alternatively, any plate-like configuration which locates the device on the inner surface of the sclera in the suprachoroidal space may be used, such as for example a rectangular foldable plate. Preferably the plate diameter is from 0.05 to 6 mm, and preferably the place thickness is from 12.5 μm to 250 μm. The fluid drainage tube of the ocular device is preferably integral with the plate, and is attached at one end to the plate, preferably at the periphery of the plate. Alternatively, the tube may be microwelded or otherwise fixed to the plate. Fabrication techniques well known in production of intraocular foldable lenses are preferably used in this invention. The tube has a hollow lumen, and is preferably of a length from about 1 mm to 4 mm. Preferred diameters of the tubing comprise an outer diameter of 400-1000 μm, and preferably the inner diameter is from 50 to 500 μm.

The diameter of the tube may be selected so as to provide a resistance to aqueous humor flow of predetermined pressure, preferably being a pressure less than 10 mm Hg. This enables the pressure of the aqueous to be regulated in a controlled manner, providing relief from excess ocular pressure associated with glaucoma, with avoidance of hypotony (uncontrolled low pressure). Alternatively, the tube may contain a valve, for example disposed at the end of the tube opening onto the disc so as to regulate ocular pressure at a predetermined level. Preferably, the valve prevents aqueous flow through the tube at a pressure of less than 10 mm Hg. Examples of valves which may be used include a slit valve. The drainage stops altogether if the pressure drops to a predetermined threshold level controlled by the valve.

The flexible foldable nature of the device according to the present invention enables well established techniques used in cataract surgery to be employed in the treatment of glaucoma. The device according to the present invention may be folded into a cannula and introduced for location into the eye.

Intraocular surgery techniques allow a paracentesis (opening onto the anterior chamber from without at the juncture of the cornea and sclera—the limbus) to be performed and the anterior chamber filled with viscoelastic substance. A cyclodialysis instrument is introduced via the paracentesis, with the paracentesis preferably being carried out 180° from the insertion site. A cyclodialysis is carried out, for example by advancing an instrument tip into the angle between the ciliary body and sclera so as to create a cyclodialysis. This is preferably carried out with direct visualisation via gonioscopy lens viewed through an operating microscope. A surgical gonioscopy lens is preferably placed on the cornea while the cyclodialysis is carried out.

The rolled up ocular device is introduced through a cannula, for example using an introducer such as used in cataract surgery or other ocular surgery, from which the device can be detached by pressing a plunger into the introducer when the device has been inserted into the suprachoroidal space created by the cyclodialysis. The tubing of the device is positioned into the interior chamber, and the plate unfolds in the suprachoroidal space to locate the device in the eye. Because of its size, the device cannot fall through the opening through which it was introduced into the suprachoroidal space by the cyclodialysis. The plate therefore keeps the tube in the appropriate position in the anterior chamber allowing controlled aqueous drainage and providing an effective treatment for elevated ocular pressure.

The pressure spike shunt is designed to fit snugly in a paracentesis port that is routinely made during cataract or other ocular surgery. The tubing will not distort the port and there will be no leakage around the port. The outer end of the tube will sit flush on the surface of the cornea—the inner aspect of the tube will preferably just protrude into the anterior chamber—tube length will generally be 1-2 mm and tube diameter is preferably from 0.4-1.2 mm. The tube will contain the same valvular device as contained in the ocular device described above and will open when the intraocular pressure exceeds a predetermined level, preferably 10 mm Hg. At normal ocular pressure the valve will be closed, closing said tube to any fluid communication. FIG. 3 shows a shunt located in a paracentesis port. In most cases the shunt will be removed and discarded at the first post-operative dressing.

The shunt may be inserted into a paracentesis port, or one or more ports, using, for example, a punctum plug inserting instrument such as described in U.S. Pat. No. 5,741,292.

This invention will now be described with reference to the following examples.

EXAMPLE 1

Fresh whole porcine eyes were taken and mounted in a temperature controlled)(37° perfusion chamber. The eyes were perfused with Balanced Salt Solution via a 30 gauge needle inserted via a paracentesis into the anterior chamber. A peristaltic pump was used at a flow rate of 2 μl/min. Intraocular pressure was continuously monitored via a second paracentesis.

Typically intraocular pressures stabilized at 10-15 mm Hg and fell with time (the “washout effect”, as glycosan aminoglycans are washed out of the trabecular meshwork with time). Creation of a cyclodialysis (initially with a small spatula, then viscoelastic injection to enlarge the area of detachment of the ciliary body from the sclera) with or without insertion of the device in the cyclodialysis cleft (silicone tubing, length 3 mm, external diameter—1 mm, plate diameter 3 mm) resulted in lower intraocular pressures (below 10 mm Hg) on reperfusion at the same perfusion rate as control eyes.

EXAMPLE 2

Adequate anesthesia is provided to the eye of a glaucoma patient prepared for intraocular surgery. A paracentesis (opening into anterior chamber from without at the junction of the cornea and sclera—the limbus) is performed and the anterior chamber is filled with a viscoelastic substance. A surgical gonioscopy lens is placed on the cornea (or anterior segment endoscope is used) and a cyclodialysis instrument is introduced via the paracentesis—the paracentesis is carried out 180° away from the planned implant insertion site. The cyclodialysis instrument tip is advanced into the angle and pushed into the space between the ciliary body and sclera creating a cyclodialysis—this is carried out with direct visualization via the gonioscopy lens viewed through an operating microscope. In order to minimize bleeding, the area in the angle (anterior ciliary body face and overlying trabecular meshwork) can be lasered either preoperatively or at the time of surgery to ablate surface blood vessels).

Through an opening at the tip of the cyclodialysis instrument viscoelastic is inserted to further create a space in the suprachoroidal space. The implant is then introduced—the device is rolled up in the same manner as an ultrathin intraocular lens. The ocular device is attached to an introducer from which it is detached by pushing a plunger in the introducer when the implant is inserted into the suprachoroidal space created by the cyclodialysis instrument and viscoelastic. The tubing is then positioned into the anterior chamber and may be cut to size. The plate unfolds in the suprachoroidal space and because of its size cannot fall through the opening through which it was introduced into the suprachoroidal space. The plate therefore keeps the tube in an appropriate position. The valve is then flushed (with a cannula inserted via the paracentesis) via the tube opening in the anterior chamber. Viscoelastic is then removed from the anterior chamber and antibiotics, steroids and a dressing applied to the eye.

EXAMPLE 3

Fresh whole porcine eyes were taken and mounted in a temperature-controlled) (37° perfusion chamber as in Example 1. The eyes were perfused with Balanced Salt Solution via a 30 gauge needle inserted via a paracentesis into the anterior chamber. A peristaltic pump was used at a flow rate of 2 μl/min. Intraocular pressure was continuously monitored via a second paracentesis.

Typically intraocular pressures stabilized at 10-15 mm Hg and fell with time (the “washout effect, as glycoaminoglycans are washed out of the trabecular meshwork with time). Silicone tubing (length 3 mm, external diameter 1 mm) was introduced into one paracentesis port. One end of the port (outer end) was flush with the cornea and the inner end of the port extended slightly into the anterior chamber. Intraocular pressure did not exceed 10 mm Hg.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US376775919 mai 197123 oct. 1973Akademie VedMethod of molding capillary drain for surgery
US378832730 mars 197129 janv. 1974Donowitz HSurgical implant device
US391517226 mars 197328 oct. 1975Ceskoslovenska Akademie VedCapillary drain for glaucoma
US40376045 janv. 197626 juil. 1977Newkirk John BArtifical biological drainage device
US440268110 sept. 19816 sept. 1983Haas Joseph SArtificial implant valve for the regulation of intraocular pressure
US445775720 juil. 19813 juil. 1984Molteno Anthony C BDevice for draining aqueous humour
US452121027 déc. 19824 juin 1985Wong Vernon GEye implant for relieving glaucoma, and device and method for use therewith
US455491828 juil. 198226 nov. 1985White Thomas COcular pressure relief device
US460408721 juin 19855 août 1986Joseph Neil HAqueous humor drainage device
US46344186 avr. 19846 janv. 1987Binder Perry SHydrogel seton
US472272423 juin 19862 févr. 1988Stanley SchocketAnterior chamber tube shunt to an encircling band, and related surgical procedure
US47509015 mars 198714 juin 1988Molteno Anthony C BImplant for drainage of aqueous humour
US47878856 mars 198729 nov. 1988Binder Perry SHydrogel seton
US482647821 août 19872 mai 1989Stanley SchocketAnterior chamber tube shunt to an encircling band, and related surgical procedure
US484617226 mai 198711 juil. 1989Berlin Michael SLaser-delivery eye-treatment method
US486345722 avr. 19885 sept. 1989Lee David ADrug delivery device
US48864884 août 198812 déc. 1989White Thomas CGlaucoma drainage the lacrimal system and method
US490030024 févr. 198913 févr. 1990Lee David ASurgical instrument
US494643617 nov. 19897 août 1990Smith Stewart GPressure-relieving device and process for implanting
US496829620 déc. 19896 nov. 1990Robert RitchTransscleral drainage implant device for the treatment of glaucoma
US504108118 mai 199020 août 1991Odrich Ronald BOcular implant for controlling glaucoma
US507140812 févr. 199010 déc. 1991Ahmed Abdul MateenMedical valve
US507316329 janv. 199017 déc. 1991Lippman Myron EApparatus for treating glaucoma
US509283727 août 19903 mars 1992Robert RitchMethod for the treatment of glaucoma
US512790131 janv. 19917 juil. 1992Odrich Ronald BImplant with subconjunctival arch
US517121314 août 199115 déc. 1992Price Jr Francis WTechnique for fistulization of the eye and an eye filtration prosthesis useful therefor
US517860431 mai 199012 janv. 1993Iovision, Inc.Glaucoma implant
US51803623 avr. 199019 janv. 1993Worst J G FGonio seton
US530002030 sept. 19925 avr. 1994Medflex CorporationSurgically implantable device for glaucoma relief
US53382913 févr. 199316 août 1994Pudenz-Schulte Medical Research CorporationGlaucoma shunt and method for draining aqueous humor
US534237019 mars 199330 août 1994University Of MiamiMethod and apparatus for implanting an artifical meshwork in glaucoma surgery
US534646414 avr. 199313 sept. 1994Camras Carl BMethod and apparatus for reducing intraocular pressure
US537060728 oct. 19926 déc. 1994Annuit Coeptis, Inc.Glaucoma implant device and method for implanting same
US537257718 févr. 199313 déc. 1994Ungerleider; Bruce A.Apparatus for reducing intraocular pressure
US539730021 avr. 199414 mars 1995Iovision, Inc.Glaucoma implant
US543370121 déc. 199418 juil. 1995Rubinstein; Mark H.Apparatus for reducing ocular pressure
US544350515 nov. 199322 août 1995Oculex Pharmaceuticals, Inc.Biocompatible ocular implants
US54547466 juil. 19943 oct. 1995Meccano, S.A.Toy hand tool
US54764451 août 199419 déc. 1995Iovision, Inc.Glaucoma implant with a temporary flow restricting seal
US555862921 juil. 199224 sept. 1996Iovision, Inc.Glaucoma implant
US555863030 déc. 199424 sept. 1996Fisher; Bret L.Intrascleral implant and method for the regulation of intraocular pressure
US560109422 nov. 199411 févr. 1997Reiss; George R.Ophthalmic shunt
US56265585 mai 19956 mai 1997Suson; JohnAdjustable flow rate glaucoma shunt and method of using same
US56265591 mai 19956 mai 1997Ramot University Authority For Applied Research And Industrial Development Ltd.Ophthalmic device for draining excess intraocular fluid
US565178213 juin 199629 juil. 1997University Of MiamiMethod and apparatus for implanting an artificial meshwork in glaucoma surgery
US56769446 oct. 199314 oct. 1997The Regents Of The University Of CaliforniaOcular therapy with homologous macrophages
US57024145 sept. 199630 déc. 1997Optonol LtdMethod of implanting an intraocular implant
US570490711 déc. 19956 janv. 1998Wound Healing Of OklahomaMethod and apparatus for lowering the intraocular pressure of an eye
US571384410 janv. 19973 févr. 1998Peyman; Gholam A.Device and method for regulating intraocular pressure
US574129228 avr. 199721 avr. 1998Eagle VisionPunctum dilating and plug inserting instrument with push-button plug release
US574386814 févr. 199428 avr. 1998Brown; Reay H.Corneal pressure-regulating implant device
US575292814 juil. 199719 mai 1998Rdo Medical, Inc.Glaucoma pressure regulator
US58073021 avr. 199615 sept. 1998Wandel; ThaddeusTreatment of glaucoma
US586869727 mars 19969 févr. 1999Optonol Ltd.Intraocular implant
US588232717 avr. 199716 mars 1999Jacob; Jean T.Long-term glaucoma drainage implant
US589383728 févr. 199713 avr. 1999Staar Surgical Company, Inc.Glaucoma drain implanting device and method
US596805814 juil. 199719 oct. 1999Optonol Ltd.Device for and method of implanting an intraocular implant
US600751025 oct. 199628 déc. 1999Anamed, Inc.Implantable devices and methods for controlling the flow of fluids within the body
US6007511 *8 mai 199128 déc. 1999Prywes; Arnold S.Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation
US601978627 août 19971 févr. 2000Schneider (Usa) IncBraided composite prosthesis
US60509708 mai 199718 avr. 2000Pharmacia & Upjohn CompanyMethod and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye
US607729922 juin 199820 juin 2000Eyetronic, LlcNon-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
US610204524 déc. 199715 août 2000Premier Laser Systems, Inc.Method and apparatus for lowering the intraocular pressure of an eye
US614296927 juil. 19987 nov. 2000Anamed, Inc.Sutureless implantable device and method for treatment of glaucoma
US618697412 janv. 199813 févr. 2001University College London And Moorfields Eye Hospital Nhs TrustDevice for use in the eye
US620351320 nov. 199720 mars 2001Optonol Ltd.Flow regulating implant, method of manufacture, and delivery device
US622107825 juin 199924 avr. 2001Stephen S. BylsmaSurgical implantation apparatus
US62510902 nov. 199826 juin 2001Robert Logan AveryIntravitreal medicine delivery
US62612563 oct. 199717 juil. 2001Abdul Mateen AhmedPocket medical valve & method
US626466816 sept. 199824 juil. 2001Arnold S. PrywesOphthalmologic instrument for producing a fistula in the sclera
US633131322 oct. 199918 déc. 2001Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
US637564215 févr. 200023 avr. 2002Grieshaber & Co. Ag SchaffhausenMethod of and device for improving a drainage of aqueous humor within the eye
US638321916 févr. 19987 mai 2002Corneal IndustrieImplant for deep sclerectomy
US645098426 avr. 200017 sept. 2002Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US646472426 avr. 200015 oct. 2002Gmp Vision Solutions, Inc.Stent device and method for treating glaucoma
US646828326 août 199922 oct. 2002Optonol, Ltd.Method of regulating pressure with an intraocular implant
US647166624 févr. 200029 oct. 2002Steven A. OdrichInjectable glaucoma device
US647177720 oct. 199929 oct. 2002Murata Manufacturing Co., Ltd.Holder for electroless plating and method of electroless plating
US650877924 janv. 199721 janv. 2003John SusonAdjustable flow rate glaucoma shunt and method of using same
US65106004 déc. 200028 janv. 2003Optonol, Ltd.Method for manufacturing a flow regulating implant
US652427526 avr. 200025 févr. 2003Gmp Vision Solutions, Inc.Inflatable device and method for treating glaucoma
US653376814 avr. 200018 mars 2003The Regents Of The University Of CaliforniaDevice for glaucoma treatment and methods thereof
US653756817 oct. 200125 mars 2003Allergan, Inc.Implant device with a retinoid for improved biocompatibility
US654420829 déc. 20008 avr. 2003C. Ross EthierImplantable shunt device
US654424928 nov. 19978 avr. 2003The Lions Eye Institute Of Western Australia IncorporatedBiological microfistula tube and implantation method and apparatus
US65583422 juin 19996 mai 2003Optonol Ltd.Flow control device, introducer and method of implanting
US65892031 août 20008 juil. 2003Peter MitrevGlaucoma drainage device implant
US65959459 janv. 200122 juil. 2003J. David BrownGlaucoma treatment device and method
US662685812 sept. 200230 sept. 2003Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US663823914 avr. 200028 oct. 2003Glaukos CorporationApparatus and method for treating glaucoma
US66482836 juil. 200118 nov. 2003Joanne M. ChaseAdjustable ornament display apparatus
US66668412 mai 200123 déc. 2003Glaukos CorporationBifurcatable trabecular shunt for glaucoma treatment
US66766073 janv. 200113 janv. 2004The Johns Hopkins UniversityIntraoperative microsurgical ultrasonic device and methods related thereto
US669921027 avr. 19992 mars 2004The Arizona Board Of RegentsGlaucoma shunt and a method of making and surgically implanting the same
US669921121 août 20012 mars 2004James A. SavageMethod and apparatus for treatment of glaucoma
US671975022 juin 200113 avr. 2004The Johns Hopkins UniversityDevices for intraocular drug delivery
US67266646 août 200127 avr. 2004Optonol Ltd.Flow control device, introducer and method of implanting
US673005621 sept. 20004 mai 2004Motorola, Inc.Eye implant for treating glaucoma and method for manufacturing same
US67367911 nov. 200018 mai 2004Glaukos CorporationGlaucoma treatment device
US674166611 janv. 200025 mai 2004Canon Kabushiki KaishaDevice and method for transforming a digital signal
US678016421 mars 200324 août 2004Glaukos CorporationL-shaped implant with bi-directional flow
US678354411 oct. 200231 août 2004Gmp Vision Solutions, Inc.Stent device and method for treating glaucoma
US682769927 mai 20037 déc. 2004Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US682770027 mai 20037 déc. 2004Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US68811971 nov. 200019 avr. 2005Anamed, Inc.Sutureless implantable device and method for treatment of glaucoma
US688119816 juin 200319 avr. 2005J. David BrownGlaucoma treatment device and method
US693929828 févr. 20036 sept. 2005Gmp Vision Solutions, IncDevice and method for monitoring aqueous flow within the eye
US69556564 déc. 200218 oct. 2005Glaukos CorporationApparatus and method for treating glaucoma
US696257318 oct. 20008 nov. 2005Wilcox Michael JC-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US696688813 janv. 200222 nov. 2005Eagle Vision, Inc.Sinus valved glaucoma shunt
US69693843 janv. 200129 nov. 2005The Johns Hopkins UniversitySurgical devices and methods of use thereof for enhanced tactile perception
US698195824 juil. 20033 janv. 2006Glaukos CorporationImplant with pressure sensor for glaucoma treatment
US698900727 janv. 200424 janv. 2006Solx, Inc.Devices and techniques for treating glaucoma
US7041077 *21 juil. 20039 mai 2006Yale UniversityUveoscleral drainage device
US709068118 sept. 200315 août 2006Allergan, Inc.Methods and apparatus for delivery of ocular implants
US70942253 mai 200222 août 2006Glaukos CorporationMedical device and methods of use of glaucoma treatment
US71350098 avr. 200214 nov. 2006Glaukos CorporationGlaucoma stent and methods thereof for glaucoma treatment
US716026416 déc. 20039 janv. 2007Medtronic-Xomed, Inc.Article and method for ocular aqueous drainage
US71635437 juin 200216 janv. 2007Glaukos CorporationCombined treatment for cataract and glaucoma treatment
US71862327 mars 20036 mars 2007Glaukoa CorporationFluid infusion methods for glaucoma treatment
US719241215 sept. 200320 mars 2007Glaukos CorporationTargeted stent placement and multi-stent therapy
US719577428 août 200227 mars 2007Carvalho Ricardo Azevedo PonteImplantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US720796516 juin 200424 avr. 2007Solx, Inc.Shunt for the treatment of glaucoma
US722023827 juil. 200422 mai 2007Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US727347521 oct. 200525 sept. 2007Glaukos CorporationMedical device and methods of use for glaucoma treatment
US729112514 nov. 20036 nov. 2007Transcend Medical, Inc.Ocular pressure regulation
US729713021 mars 200320 nov. 2007Glaukos CorporationImplant with anchor
US733198428 août 200219 févr. 2008Glaukos CorporationGlaucoma stent for treating glaucoma and methods of use
US743171018 mars 20057 oct. 2008Glaukos CorporationOcular implants with anchors and methods thereof
US748830322 sept. 200310 févr. 2009Glaukos CorporationOcular implant with anchor and multiple openings
US756324113 nov. 200621 juil. 2009Glaukos CorporationImplant and methods thereof for treatment of ocular disorders
US78577825 févr. 200928 déc. 2010Glaukos CorporationOcular implant delivery system and method thereof
US8128588 *22 déc. 20066 mars 2012Transcend Medical, Inc.Ocular pressure regulation
US200100005274 déc. 200026 avr. 2001Optonol Ltd.Flow regulating implant, method of manufacture, and delivery device
US200100251503 janv. 200127 sept. 2001De Juan EugeneSurgical devices and methods of use thereof for enhanced tactile perception
US2002001354617 sept. 200131 janv. 2002Grieshaber & Co. Ag SchaffhausenMethod and device to improve aqueous humor drainage in an eye
US2002001357221 mai 200131 janv. 2002Berlin Michael S.Delivery system and method of use for the eye
US2002002620021 août 200128 févr. 2002Savage James A.Method and apparatus for treatment of glaucoma
US2002007267311 déc. 200013 juin 2002Yamamoto Ronald K.Treatment of ocular disease
US2002008711129 déc. 20004 juil. 2002Ethier C. RossImplantable shunt device
US2002011160818 janv. 200215 août 2002George BaerveldtMinimally invasive glaucoma surgical instrument and method
US2002012861325 mai 200112 sept. 2002Masanari NakayamaMethod of treating eye diseases of animals and artificial lacrimal duct used therefor
US2002013316818 mars 200219 sept. 2002Smedley Gregory T.Applicator and methods for placing a trabecular shunt for glaucoma treatment
US200201432848 nov. 20013 oct. 2002Hosheng TuDrug-releasing trabecular implant for glaucoma treatment
US2002015641327 avr. 199924 oct. 2002Stuart K. WilliamsGlaucoma shunt and a method of making and surgically implanting the same
US200201654782 mai 20017 nov. 2002Morteza GharibBifurcatable trabecular shunt for glaucoma treatment
US200201691303 mai 200214 nov. 2002Hosheng TuMedical device and methods of use for glaucoma treatment
US200201694689 janv. 200114 nov. 2002J.David BrownGlaucoma treatment device and method
US200201778569 juil. 200228 nov. 2002Jacob RichterIntraocular implant, delivery device, and method of implantation
US200201883088 avr. 200212 déc. 2002Hosheng TuGlaucoma stent and methods thereof for glaucoma treatment
US2002019372513 juin 200219 déc. 2002Odrich Steven A.Injectable glaucoma device
US2003000912412 sept. 20029 janv. 2003Lynch Mary G.Shunt device and method for treating glaucoma
US2003002822828 août 20026 févr. 2003Sand Bruce J.Treatment of collagen
US2003005537216 août 200220 mars 2003Lynch Mary G.Shunt device and method for treating glaucoma
US200300607521 mai 200227 mars 2003Olav BergheimGlaucoma device and methods thereof
US2003006963711 oct. 200210 avr. 2003Lynch Mary G.Stent device and method for treating glaucoma
US200300882607 juin 20028 mai 2003Smedley Gregory T.Combined treatment for cataract and glaucoma treatment
US2003009715125 oct. 200222 mai 2003Smedley Gregory T.Apparatus and mitochondrial treatment for glaucoma
US2003009717120 nov. 200122 mai 2003Elliott Christopher J.Stent with differential lengthening/shortening members
US200301202004 déc. 200226 juin 2003Bergheim Olav B.Apparatus and method for treating glaucoma
US2003013514913 janv. 200217 juil. 2003Cheryl CullenSinus valved glaucoma shunt
US2003018184821 mars 200325 sept. 2003Bergheim Olav B.Implant with drug coating
US2003018738421 mars 20032 oct. 2003Bergheim Olav B.Implant with a micropump
US2003018738521 mars 20032 oct. 2003Bergheim Olav B.Implant with anchor
US2003019142821 mars 20039 oct. 2003Bergheim Olav B.L-shaped implant with bi-directional flow
US200302081636 août 20016 nov. 2003Optonol Ltd.Flow control device, introducer and method of implanting
US2003022060227 mai 200327 nov. 2003Lynch Mary G.Shunt device and method for treating glaucoma
US2003022060327 mai 200327 nov. 2003Lynch Mary G.Shunt device and method for treating glaucoma
US2003022930321 mars 200311 déc. 2003Haffner David S.Expandable glaucoma implant and methods of use
US2003023201528 févr. 200318 déc. 2003Reay BrownDevice and method for monitoring aqueous flow within the eye
US2003023648325 juin 200225 déc. 2003Ren David HDual drainage ocular shunt for glaucoma
US2003023648423 janv. 200325 déc. 2003Gmp Vision Solutions, Inc.Inflatable device and method for treating glaucoma
US2004001514021 juil. 200322 janv. 2004Shields Milton B.Uveoscleral drainage device
US2004002434518 avr. 20035 févr. 2004Morteza GharibGlaucoma implant with valveless flow bias
US2004005039228 août 200218 mars 2004Hosheng TuGlaucoma stent for treating glaucoma and methods of use
US2004007315616 juin 200315 avr. 2004Brown J. DavidGlaucoma treatment device and method
US2004008804827 oct. 20036 mai 2004Jacob RichterIntraocular implant, delivery device, and method of implantation
US2004009285631 août 200113 mai 2004Elie DahanGlaucoma drain
US200401027295 août 200327 mai 2004David HaffnerDevices and methods for glaucoma treatment
US200401110507 août 200310 juin 2004Gregory SmedleyImplantable ocular pump to reduce intraocular pressure
US2004012784312 nov. 20031 juil. 2004Hosheng TuGlaucoma implant with therapeutic agents
US2004014787028 oct. 200329 juil. 2004Burns Thomas W.Glaucoma treatment kit
US2004014802216 janv. 200429 juil. 2004Eggleston Harry C.Modular intraocular implant
US2004019309517 janv. 200430 sept. 2004Shadduck John H.Implants for treating ocular hypertension, methods of use and methods of fabrication
US200401932623 févr. 200430 sept. 2004Shadduck John H.Implants for treating ocular hypertension, methods of use and methods of fabrication
US2004021018126 avr. 200221 oct. 2004Clemens VassDrainage implant for draining aqueous humour from the anterior aqueous chamber of the eye into schlemm's canal
US2004021018519 févr. 200421 oct. 2004Hosheng TuGlaucoma implant kit
US2004021674923 janv. 20044 nov. 2004Hosheng TuVasomodulation during glaucoma surgery
US200402252505 mai 200311 nov. 2004Michael YablonskiInternal shunt and method for treating glaucoma
US2004023634323 mai 200325 nov. 2004Taylor Jon B.Insertion tool for ocular implant and method for using same
US2004024933312 juil. 20049 déc. 2004Bergheim Olav B.Glaucoma implant with bi-directional flow
US2004025451718 févr. 200416 déc. 2004Hugo Quiroz-MercadoMethods and devices for draining fluids and lowering intraocular pressure
US2004025451914 avr. 200416 déc. 2004Hosheng TuGlaucoma treatment device
US200402545202 juin 200416 déc. 2004Eric PorteousCoil implant for glaucoma treatment
US2004025452116 juin 200416 déc. 2004Solx, Inc.Shunt for the treatment of glaucoma
US2004026022716 déc. 200323 déc. 2004Lisk James R.Article and method for ocular aqueous drainage
US2004026022823 juil. 200423 déc. 2004Lynch Mary G.Stent device and method for treating glaucoma
US200500086739 avr. 200413 janv. 2005Michael SnyderSustained release surgical device and method of making and using the same
US2005003833427 juil. 200417 févr. 2005Lynch Mary G.Shunt device and method for treating glaucoma
US200500495784 août 20043 mars 2005Hosheng TuImplantable ocular pump to reduce intraocular pressure
US2005009080612 nov. 200428 avr. 2005Gmp Vision Solutions Inc.Shunt device and method for treating glaucoma
US2005009080712 nov. 200428 avr. 2005Gmp Vision Solutions, Inc.Shunt device and method for treating glaucoma
US2005010773414 nov. 200319 mai 2005Coroneo Minas T.Ocular pressure regulation
US2005011960116 août 20022 juin 2005Lynch Mary G.Shunt device and method for treating glaucoma
US2005011963624 sept. 20042 juin 2005David HaffnerImplant with intraocular pressure sensor for glaucoma treatment
US200501197371 juin 20042 juin 2005Bene Eric A.Ocular implant and methods for making and using same
US200501250033 déc. 20049 juin 2005Leonard PinchukGlaucoma implant device
US200501438177 déc. 200430 juin 2005Angiotech International AgMedical implants and anti-scarring agents
US2005014908030 nov. 20047 juil. 2005Angiotech International AgMedical implants and anti-scarring agents
US200501756632 déc. 200411 août 2005Angiotech International AgMedical implants and anti-scarring agents
US200501810112 déc. 200418 août 2005Angiotech International AgMedical implants and anti-scarring agents
US2005018197710 nov. 200418 août 2005Angiotech International AgMedical implants and anti-scarring agents
US2005018235018 avr. 200518 août 2005Alok NigamSutureless implantable device and method for treatment of glaucoma
US2005019133130 nov. 20041 sept. 2005Angiotech International AgMedical implants and anti-scarring agents
US200501925274 mai 20051 sept. 2005Morteza GharibGlaucoma implant with extending members
US2005019761324 déc. 20048 sept. 2005Sniegowski Jeffry J.Implant having MEMS flow module with movable, flow-controlling baffle
US200502095496 mai 200522 sept. 2005Bergheim Olav BGlaucoma implant with multiple openings
US200502095506 mai 200522 sept. 2005Bergheim Olav BMethod of treating glaucoma using an implant having a uniform diameter between the anterior chamber and Schlemm's canal
US2005023297215 avr. 200420 oct. 2005Steven OdrichDrug delivery via punctal plug
US2005024446230 avr. 20043 nov. 2005Allergan, Inc.Devices and methods for treating a mammalian eye
US2005025078827 janv. 200510 nov. 2005Hosheng TuAqueous outflow enhancement with vasodilated aqueous cavity
US2005026604718 mars 20051 déc. 2005Hosheng TuInjectable glaucoma implants with multiple openings
US2005026739717 mai 20051 déc. 2005Ajay BhallaAqueous drainage and flow regulating implant
US2005026739825 mai 20051 déc. 2005Dimitri ProtopsaltisGlaucoma shunt
US2005027170418 mars 20058 déc. 2005Hosheng TuInjectable glaucoma implants with multiple openings
US2005027303329 mai 20038 déc. 2005Grahn Bruce HShunt and method treatment of glaucoma
US2005027786411 mai 200515 déc. 2005David HaffnerInjectable gel implant for glaucoma treatment
US2005028310810 juin 200522 déc. 2005Savage James AApparatus and method for non-pharmacological treatment of glaucoma and lowering intraocular pressure
US2005028861725 juin 200429 déc. 2005Ira YaronFlow regulating implants
US2005028861923 août 200529 déc. 2005Morteza GharibBiodegradable glaucoma implant
US2006002024826 juil. 200426 janv. 2006Prescott Anthony DLacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US2006003250711 août 200416 févr. 2006Hosheng TuContrast-enhanced ocular imaging
US2006003620723 août 200516 févr. 2006Koonmen James PSystem and method for treating glaucoma
US2006004726321 oct. 20052 mars 2006Hosheng TuMedical device and methods of use for glaucoma treatment
US200600693403 nov. 200530 mars 2006Solx, Inc.Shunt for the treatment of glaucoma
US200600743756 déc. 20056 avr. 2006Bergheim Olav BShunt device and method for treating glaucoma
US200600849076 déc. 200520 avr. 2006Bergheim Olav BShunt device and method for treating glaucoma
US2006011662612 janv. 20061 juin 2006Gregory SmedleyFluid infusion methods for glaucoma treatment
US2006014919421 nov. 20026 juil. 2006Conston Stanley ROphthalmic microsurgical system
US2006015523813 mars 200613 juil. 2006Shields Milton BUveoscleral drainage device
US2006017339722 nov. 20053 août 2006Hosheng TuOphthalmology implants and methods of manufacture
US2006019505527 avr. 200631 août 2006Bergheim Olav BShunt device and method for treating glaucoma
US2006019505627 avr. 200631 août 2006Bergheim Olav BShunt device and method for treating glaucoma
US2006020011313 févr. 20067 sept. 2006David HaffnerLiquid jet for glaucoma treatment
US2006023536718 déc. 200319 oct. 2006Seisuke TakashimaAqueous humor drainage implant for treatment glaucoma
US2006024158010 juin 200426 oct. 2006Neomedix CorporationDevice and methods useable for treatment of glaucoma and other surgical procedures
US2006024174919 juin 200626 oct. 2006Hosheng TuGlaucoma stent system
US2006027673919 déc. 20057 déc. 2006Brown J DGlaucoma treatment device and method
US2007001082719 juin 200611 janv. 2007Hosheng TuGlaucoma stent system
US2007008842421 sept. 200619 avr. 2007William A. Cook Australia Pty Ltd.Endoluminal delivery assembly
US2007008843223 oct. 200619 avr. 2007Kenneth SolovayIndwelling shunt device and methods for treating glaucoma
US2007011229213 nov. 200617 mai 2007Hosheng TuGlaucoma stent and methods thereof for glaucoma treatment
US2007011814716 janv. 200724 mai 2007Smedley Gregory TCombined treatment for cataract and glaucoma treatment
US2007019186322 déc. 200616 août 2007De Juan Eugene JrGlaucoma Treatment Device
US200702763158 août 200729 nov. 2007Glaukos CorporationDevices and methods for glaucoma treatment
US200702763168 août 200729 nov. 2007Glaukos CorporationDevices and methods for glaucoma treatment
US200702822448 août 20076 déc. 2007Glaukos CorporationGlaucoma implant with anchor
US200702822458 août 20076 déc. 2007Glaukos CorporationGlaucoma implant with valve
US2007029380730 avr. 200720 déc. 2007Lynch Mary GDual drainage pathway shunt device and method for treating glaucoma
US2008001548825 sept. 200717 janv. 2008Glaukos CorporationGlaucoma implant with double anchor mechanism
US2008004587820 août 200721 févr. 2008Glaukos CorporationTherapeutic shunt device and method for treating glaucoma
US20080108933 *29 juin 20078 mai 2008Dao-Yi YuMethods, Systems and Apparatus for Relieving Pressure in an Organ
US2008020086028 avr. 200821 août 2008Glaukos CorporationSystem for treating ocular disorders and methods thereof
US200802281279 nov. 200718 sept. 2008Glaukos CorporationUveoscleral shunt and methods for implanting same
US2008023462412 juil. 200425 sept. 2008Glaukos CorporationOcular implant with anchor and therapeutic agent
US200900368196 oct. 20085 févr. 2009Glaukos CorporationDrug eluting ocular implant with anchor and methods thereof
US2010001041617 sept. 200914 janv. 2010Juan Jr Eugene DeGlaucoma treatment device
US2010015264123 févr. 201017 juin 2010Michael YablonskiInternal shunt and method for treating glaucoma
US2010027425926 mars 201028 oct. 2010Optonol Ltd.Fluid drainage device, delivery device, and associated methods of use and manufacture
US2011002888414 oct. 20103 févr. 2011Minas Theodore CoroneoOcular pressure regulation
US2011008714917 déc. 201014 avr. 2011Minas Theodore CoroneoOcular pressure regulation
US2011008715017 déc. 201014 avr. 2011Minas Theodore CoroneoOcular pressure regulation
US20120123316 *15 nov. 201017 mai 2012Aquesys, Inc.Intraocular shunts for placement in the intra-tenon's space
EP0228185B126 nov. 198625 juil. 1990Thomas C. WhiteTissue-implantable fluid-dissipating device
EP1184010A229 août 20016 mars 2002Aixmed Gesellschaft für Medizintechnik mbHAqueous humour drainage device
EP1310222A35 nov. 200217 mars 2004Glaukos CorporationDrug-releasing trabecular implant for glaucoma treatment
EP1418868B18 avr. 200226 mars 2008Glaukos CorporationGlaucoma stent for glaucoma treatment
EP1473004A213 mai 19963 nov. 2004Optonol Ltd.Ophtalmic implant for treating glaucoma and delivery device
EP1477146B126 avr. 200026 août 2009Glaukos CorporationShunt device for treating glaucoma
EP1977724A18 avr. 20028 oct. 2008Glaukos CorporationSystem for treating ocular disorders
EP2027837B126 avr. 200021 oct. 2015Glaukos CorporationShunt device and method for treating glaucoma
GB2101891A Titre non disponible
RU2018289C1 Titre non disponible
RU2056818C1 Titre non disponible
RU2074686C1 Titre non disponible
RU2074687C1 Titre non disponible
RU2157678C1 Titre non disponible
WO2004026106A218 sept. 20031 avr. 2004Allergan, Inc.Methods and apparatus for delivery of ocular implants
WO2004073552A218 févr. 20042 sept. 2004Hampar KarageozianMethods and devices for draining fluids and lowering intraocular pressure
Citations hors brevets
Référence
1Barsky et al. "Evaluation of absorbable gelatin film (Gelfilm) in cyclodialysis clefts" Arch. Ophth. 60(6): 1044-1052, 1958.
2Bick M.W., "Use of tantalum for ocular drainage" Arch Ophthal. Oct. 1949; 42(4): 373-88.
3Bietti, G., "The present state of the use of plastics in eye surgery" Acta Ophthalmol (Copenh) 1955; 33(4):337-70.
4Brown et al., "Internal Sclerectomy for Glaucoma Filtering Surgery with an Automated Trephine," Archives of Ophthalmology, vol. 105, Jan. 1987.
5Burchfield JC, Kass MA, Wax MB. Primary valve malfunction of the Krupin eye valve with disk. J Glaucoma. Jun. 1997;6(3):152-6.
6Chiou et al. "Ultrasound biomicroscopy of eyes undergoing deep sclerectomy with collagen implant" Br J Ophthalmol 80 (1996), pp. 541-544.
7Chylack LT, Bellows AR. Molecular sieving in suprachoroidal fluid formation in man. Invest Ophthalmol Vis Sci 17: 420, 1978.
8Classen et al., "A histopathologic and immunohistorchemical analysis of the filtration bleb after unsuccessful glaucoma seton implantation" Am. J. Ophthalmol. 122:205-12 (1996).
9Cohen et al., "First day post-operative review following uncomplicated phacoemulsification" Eye 12(4):634-6 (1998).
10Collaborative Normal-Tension Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
11Demailly et al. "Non-penetrating deep sclerectomy (NPDS) with or without collagen device (CD) in primary open-angle glaucoma: middle-term retrospective study" International Ophthalmology 20: 131-140, 1997.
12Derwent English abstract for EP 1184010, published Mar. 6, 2002 entitled: "Drainage unit for an eye, consists of a hollow line, a distribution member, and a pressure relief valve which only allows water to leave the eye chamber above a certain pressure," Accession Nbr. 12409716 [351].
13Dinakaran et al., "Is the first post-operative day review necessary following uncomplicated phacoemulsification surgery?" Eye, 14(3A):364-6 (2000).
14Draeger "Chirurgische Mabetanahmen bei kongenitalem Glaukom" (Surgical Interventions in Congenital Glaucoma) Klin Monatsbl Augenheilkd 1993; 202(5): 425-427 [Article in German with English summary included].
15Draeger "Chirurgische Maβnahmen bei kongenitalem Glaukom" (Surgical Interventions in Congenital Glaucoma) Klin Monatsbl Augenheilkd 1993; 202(5): 425-427 [Article in German with English summary included].
16Einmahl et al., "Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye" Invest Ophthalmol Vis Sci. 43:1533-1539 (2002).
17Ellis, RA "A Reduction of Intraocular Pressure Using Plastics in Surgery" Am J Ophth. 50; 1960, 733-742.
18Emi et al., "Hydrostatic pressure of the suprachoroidal space" Invest. Ophthal. Visual Sci. 30(2):233-238 (1989).
19Fanous MM, Cohn RA. Propionibacterium endophthalmitis following Molteno tube repositioning. J Glaucoma. Aug. 1997;6(4):201-2.
20Fuchs E., "Detachment of the choroid inadvertently during cataract surgery" [German] von Graefes Arch Ophthalmol, 51:199-224 (1900) [Article in German with English summary].
21Gills et al., "Action of cyclodialysis utilizing an implant studied by manometry in a human eye" Expl Eye Res 1967; 6:75-78.
22Gills JP, "Cyclodialysis implants" South Med J. 1967 60(7):692-5.
23Gills, "Cyclodialysis Implants in Human Eyes" Am J Ophth 61:1966,841-846.
24Goldberg "Management of Uncontrolled Glaucoma With the Molteno System" Australian and New Zealand Journal of Ophthalmology 1987; 15: 97-107.
25Gordon MO, Kass. MA, for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Design and baseline description of the participants. Arch Ophthalmol 1999;573-83.
26Grant, W.M. , MD, Further Studies on Facility of Flow Through the Trabecular Meshwork, A.M.A. Archives of Ophthalmololgy, Oct. 1958, vol. 60, pp. 523-533.
27Gross et al., "Surgical therapy of chronic glaucoma in aphakia and pseudophakia" Ophthalmology, 95:1195-201 (1988).
28Harper SL, Foster CS. Intraocular lens explantation in uveitis. Int Ophthalmol Clin. 2000 Winter; 40(1):107-16.
29Harrington "Cataract and glaucoma. Management of the coexistent conditions and a description of a new operation combining lens extraction with reverse cyclodialysis." Am J Ophthalmol. May 1966;61(5 Pt 2):1134-40.
30Heijl A, Leske MC, Bengtsson B, et al for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
31Heine I., "Cyclodialysis, a new glaucoma operation" Dtsch Med Wochenschr, 31:824-826 (1905) [Article in German with English summary included].
32Hildebrand et al., "Efficacy of anterior chamber decompression in controlling early intraocular pressure spikes after uneventful phacoemulsification" J. Catact Refract Surg., 29:1087-92 (2003).
33Hoskins, et al., "Aqueous Humor Outflow", Becker-Shaffer's Diagnosis and Therapy of the Glaucomas, 6th Edition, Chapter 4, pp. 41-66, 1989.
34Howorth DJ, "Feasibility study for a micromachined glaucoma drainage device" Cranfield University School of industrial and manufacturing science MSc Thesis Academic Year 2001-2002 Sep. 13, 2002.
35Hylton et al., "Update on prostaglandin analogs" Curr Opin Ophthalmol, 14:65-9 (2003).
36Javitt JC, Chiang YP. Preparing for managed competition. Utilization of ambulatory eye care visits to ophthalmologists. Arch Ophthalmol 1993;111:1034-5.
37Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open-angle glaucoma relative to severity of disease. Eye 1989; 3:528-35.
38Jordan J., "A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma" J. Glaucoma 2006; 15:200-205.
39Karlen, M. et al., "Deep sclerectomy with collagen implant: medium term results" Br. J. Ophthalmol, Jan. 1999, 83(1):6-11.
40Kass MA, Heuer DK, Higginbotham EJ, et al for the Ocular Hypertension Treatment Study Group. The Ocular HypertensionTreatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
41Klemm et al. "Die Ultraschallbiomikroskopie als Kriterium der Funktionsprüfung des suprachorioidalen Spaltes nach kammerwinkelchirurgischen Eingriffen (Ultrasound Biomicroscopic Imaging for Assessment of the Suprachoroidal Cleft after Angle Surgery)" Klinische Monatsblätter für Augenheilkunde 1997; 210: 74-77.
42Klemm et al., "Experimental use of space-retaining substances with extended duration: functional and morphological results" Graefes Arch Clin Exp Ophthalmol Sep. 1995; 233(9):592-7.
43Kozlov et al., "Nonpenetrating deep sclerectomy with collagen" Eye microsurgery 3:44-46 (1990) [Article in Russian with English translation included].
44Krejcí L. "Microdrainage of anterior chamber of eye glaucoma operation using hydron capillary drain." Acta Univ Carol Med Monogr. 1974;(61):1-90.
45Krejci, L., "Cyclodialysis with hydroxymethyl methacrylate capillary strip (HCS). Animal experiments with a new approach in glaucoma drainage surgery" Ophthalmologica 1972; 164(2):113-21.
46Kupfer "Studies on intraocular pressure. I. A technique for polyethylene tube implantation into the anterior chamber of the rabbit." Arch Ophthalmol. Apr. 1961;65:565-70.
47La Rocca "Gonioplasty in Glaucoma*A Preliminary Report" Br J Ophth 46:1962, 404-415.
48Law et al., "Retinal Complications After Aqueous Shunt Surgical Procedures for Glaucoma" Arch Ophthal.; Dec. 1996; vol. 114:1473-1480.
49Lee et al. "Aqueous-venous shunt and intraocular pressure. Preliminary report of animal studies." Investigative Ophthalmology. vol. 5 No. 1: 59-64. Feb. 1966.
50Lee et al., "Magnetic resonance imaging of the aqueous flow in eyes implanted with the trabeculo-suprachoroidal glaucoma seton" Invest. Ophthalmol. Vis. Sci. 33:948 (1992).
51Lee KY. Trabeculo-suprachoroidal shunt for treating recalcitrant and secondary glaucoma. Presented at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, 1991.
52Leske MC, Heijl A, Hussein M, et al for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56.
53Lichter PR, Musch DC, Gillespie BW, et al and the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
54Losche, W., "Proposals for improvement of cyclodialysis" Klin Monatsblatter Augenheilkd Augenarztl Fortbild 1952 121(6):715-6 [Article in German with English translation included].
55Marx et al., "Use of the Ganciclovir implant in the Treatment of Recurrent Cytomegalovirus Retinitis" Arch Ophthal.; Jul. 1996; vol. 114:815-820.
56McPherson "Combined Trabeculotomy and Cataract Extraction as a Single Operation" Tr. Am. Ophth. Soc., vol. LXXIV, 1976; 251-260.
57Mehta KR. "The suprachoroidal hema wedge in glaucoma surgery" American Academy of Ophthalmology meeting 1977 pp. 144.
58Migdal C, Gregory W, Hitchings R. Long term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-7.
59Miglior S, Zeyen T, Pfeiffer N, et al for the European Glaucoma Prevention Study Group. The European Glaucoma Prevention Study design and baseline description of the participants. Ophthalmology 2002;109:1612-21.
60Miki, MD et al., "Intraocular Cannula for Continuous, Chronic Drug Delivery-Histopathic Observations and Function" Arch Ophthal.; May 1985; vol. 103:712-717.
61Miki, MD et al., "Intraocular Cannula for Continuous, Chronic Drug Delivery—Histopathic Observations and Function" Arch Ophthal.; May 1985; vol. 103:712-717.
62Molteno et al. "Long tube implants in the management of glaucoma" South African Medical Journal, Jun. 26, 1976;50(27):1062-6.
63Molteno et al. "The Vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma." Australian and New Zealand Journal of Ophthalmology 1986; 14: 343-354.
64Moses RA "Detachment of ciliary body-anatomical and physical considerations" Investigative Ophthalmology & Visual Science, Assoc. for Research in Vision and Ophthalmology, US, vol. 4, No. 5, Oct. 1, 1965.
65Nesterov, AP, et al., "Surgical stimulation of the uveoscleral outflow. Experimental studies on enucleated human eyes" Acta Opthalmol (Copenh) June; 57(3):409-17 (1979).
66Nguyen et al., "Complications of Baerveldt Glaucoma Drainage Implants" Arch Ophthal.; May 1998; vol. 116:571-575.
67O'Brien et al. "Cyclodialysis" Arch Ophthal. 1949;42(5):606-619.
68Olsen, Timothy W., et al., Cannulation of the Suprachoroidal Space: A Novel Drug Delivery Methodology to the Posterior Segment, American Journal of Ophthalmology, vol. 142, No. 5, Nov. 2006, pp. 777-787.e2.
69Ozdamar, A., et al., "Suprachoroidal seton implantation in refractory glaucoma: a novel surgical technique" J. Glaucoma Aug. 2003; 12(4):354-9.
70Pinnas, G. et al. "Cyclodialysis with teflon tube implants" Am J. Ophthalmol 1969 Nove; 68(5):879-883.
71Portney GL, "Silicone elastomer implantation cyclodialysis." Arch Ophthalmol 1973; 89: 10-12.
72Pruett et al., "The Fishmouth Phenomenon-II. Wedge Scleral Buckling" Arch Ophthal.; Oct. 1977; vol. 95:1782-1787.
73Pruett et al., "The Fishmouth Phenomenon—II. Wedge Scleral Buckling" Arch Ophthal.; Oct. 1977; vol. 95:1782-1787.
74Qadeer "Acrylic Gonio-Subconjunctival Plates in Glaucoma Surgery" Br J Ophthalmol. Jun. 1954; 38(6): 353-356.
75Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38:83-91.
76Richards et al. "Artificial Drainage Tubes for Glaucoma" Am J Ophth 60:1965,405-408.
77Ritch R, Shields MB, Krupin T. The Glaucomas. St. Louis: Mosby, 1996; 337-343).
78Rohen, Johannes W., Anatomy of the Aqueous Outflow Channels, Glaucoma, vol. 1, Chapter 14, pp. 277-296, Edited by J.E. Cairns, Grune & Stratton, Harcourt Brace Jovanovich Publishers, 1986.
79Rosenberg, L., et al. "Implants in glaucoma surgery" Chapter 88, The Glaucomas, Ritch et al. Eds. 2nd Ed. Mosby St. Louis 1986; p. 1783-1807.
80Row, H., "Operation to control glaucoma: preliminary report" (1934) Arch. Ophthal 12:325.
81Rowan, Patrick J., MD, Combined Cyclodialysis and Cataract Surgery, Ophthalmic Surgery and Lasers, Dec. 1998, vol. 29, No. 12, pp. 962-968 (9 pages.).
82Sampimon "A New Approach to Filtering Glaucoma Surgery" Ophthalmologica (Basel) 151: 1966, 637-644.
83Schappert S. Office visits for glaucoma: United States, 1991-92. Advance data from vital and health statistics. vol. 262. Hyattsville, MD: National Center for Health Statistics, 1995.
84Shaffer RN, Weiss DI. Concerning cyclodialysis and hypotony. Arch Ophthalmol 68: 25, 1962.
85SOLX Clinical Literature Handout; Industry Show Feb. 2006; "The SOLX Gold Micro-shunt shunt (GMS) treatment".
86Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-7.
87Sourdille et al. "Reticulated hyaluronic acid implant in non-perforating trabecular surgery." J Cataract Refract Surg 25: 332-339. (1999).
88Spiegel et al. "Schlemm's Canal Implant: A New Method to Lower Intraocular Pressure in Patients With POAG?" Ophthalmic Surgery and Lasers. vol. 30, No. 6: 492-494. Jun. 1999.
89Srinivasan, R., et al., "Microbial contamination of the anterior chamber during phacoemulsification" J. Cataract Refract Surg. 28:2173-6 (2002).
90Suguro K, et al. Uveoscleral outflow following cyclodialysis in the monkey eye using a fluorescent tracer. Invest Ophthalmol Vis Sci 1985: 26, 810.
91The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
92The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results. Am J Ophthahnol 1995;120:718-31.
93The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology 1990;97:1403-13.
94Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74.
95Toris CB. Extravascular albumin concentration of the uvea. Invest Ophthalmol Vis Sci 1990; 31: 43.
96Toris et al. "Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye." Investigative Ophthalmology & Visual Science. 26 (1985) 1745-1749.
97Toris, C., et al., "Aqueous humor dynamics in the aging human eye" Am J. Ophthalmol., 127:407-12 (1999).
98Troncosco, U.M., "Cyclodialysis with insertion of metal implant in treatment of glaucoma Preliminary report" Arch. Ophthal. 23:270 (1940).
99Troncoso, Manuel U., Tantalum implants for inducing hypotny, Am Journal of Ophthalmology, vol. 32(4):499-508 (1949).
100Veen et al. "The gonioseton, a surgical treatment for chronic glaucoma" Documenta Ophthalmologica vol. 75, Nos. 3-4, 365-375.
101Wagner, Justin A., et al., Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused under Constant Pressure, Invest Ophthalmol Vis Sci., Published in edited form in Sep. 2004, vol. 45, Issue 9, pp. 3203-3206.
102Yablonski, "Trabeculectomy with Internal Tube Shunt: a novel glaucoma surgery" J. Glaucoma 14:91-97 (2005).
103Yablonski, M., "Some thoughts on the pressure dependence of uveoscleral flow" Journal of Glaucoma, 12(1):90-92 (2003).
104Zhou, J., et al., "A trabecular bypass flow hypothesis" J Glaucoma. 14(1):74-83 (2005).
Classifications
Classification aux États-Unis604/8, 606/108, 604/9
Classification internationaleA61F11/00, A61M5/00, A61F9/007
Classification coopérativeA61F2/148, A61F9/00781
Événements juridiques
DateCodeÉvénementDescription
31 janv. 2011ASAssignment
Owner name: TRANSCEND MEDICAL, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORONEO, MINAS THEODORE;REEL/FRAME:025720/0950
Effective date: 20070429
13 juin 2016ASAssignment
Owner name: NOVARTIS AG, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSCEND MEDICAL, INC.;REEL/FRAME:038967/0487
Effective date: 20160608